TABLE 1.
DSM-5 Substance-Related Disorders Work Groupa
| Name | Degree(s) | Specialization | Country |
|---|---|---|---|
| Charles O’Brien (chair)b | M.D., Ph.D. | Addiction psychiatry | USA |
| Marc Auriacombe | M.D. | Addiction psychiatry | France |
| Guilherme Borges | Sc.D. | Epidemiology | Mexico |
| Kathleen Bucholz | Ph.D. | Epidemiology | USA |
| Alan Budney | Ph.D. | Substance use disorder treatment, marijuana | USA |
| Wilson Comptonb | M.D., M.P.E | Epidemiology, addiction psychiatry | USA |
| Thomas Crowleyc | M.D. | Psychiatry | USA |
| Bridget F. Grantb | Ph.D., Ph.D. | Epidemiology, biostatistics, survey research | USA |
| Deborah S. Hasin | Ph.D. | Epidemiology of substance use and psychiatric disorders | USA |
| Walter Ling | M.D. | Addiction psychiatry | USA |
| Nancy M. Petry | Ph.D. | Substance use and gambling treatment | USA |
| Marc Schuckit | M.D. | Genetics and comorbidity | USA |
a
In addition to the scientists listed here who were members during the entire duration of the process, a list of consultants and advisers who served on various subcommittees and contributed substantially to the discussion is contained in the official publication of DSM-5.
b
Also a DSM-5 Task Force member.
c
Co-chair, 2007–2011.